IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced a new set of…

Click here to view original post